A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials-Reference-Cited by-同舟云学术

A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

Published:2023-10 Issue:10 Volume:4 Page:710-727.e5
ISSN:2666-6340
Container-title:Med
language:en
Short-container-title:Med

Author:

Hernando-Calvo Alberto^ORCID,Vila-Casadesús Maria,Bareche Yacine,Gonzalez-Medina Alberto,Abbas-Aghababazadeh Farnoosh,Lo Giacco Deborah,Martin Agatha,Saavedra Omar,Brana Irene,Vieito Maria,Fasani Roberta,Stagg John,Mancuso Francesco,Haibe-Kains Benjamin,Han Ming,Berche Roger,Pugh Trevor J.,Mirallas Oriol,Jimenez Jose,Gonzalez Nadia Saoudi,Valverde Claudia,Muñoz-Couselo Eva,Suarez Cristina,Diez Marc,Élez Elena,Capdevila Jaume,Oaknin Ana,Saura Cristina,Macarulla Teresa,Galceran Joan Carles,Felip Enriqueta,Dienstmann Rodrigo,Bedard Philippe L.,Nuciforo Paolo,Seoane Joan,Tabernero Josep,Garralda Elena,Vivancos Ana

Publisher

Elsevier BV

Subject

General Medicine

Reference69 articles.

1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer;Reck;N. Engl. J. Med.,2016

2. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019

3. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study;Marabelle;Lancet Oncol.,2020

4. Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT);Saavedra Santa Gadea;J. Clin. Oncol.,2021

5. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types;McGrail;Ann. Oncol.,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab;JCO Precision Oncology;2024-08

2. A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies;Cancer Treatment Reviews;2024-07

3. Transcriptome Deconvolution Reveals Absence of Cancer Cell Expression Signature in Immune Checkpoint Blockade Response;Cancer Research Communications;2024-06-26

4. A computational pipeline for identifying gene targets and signalling pathways in cancer cells to improve lymphocyte infiltration and immune checkpoint therapy efficacy;eBioMedicine;2024-06

5. Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohorts;2024-04-22